ProfileGDS4814 / ILMN_1765132
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 70% 73% 72% 70% 74% 71% 74% 74% 71% 74% 71% 73% 73% 73% 73% 71% 72% 72% 72% 70% 74% 68% 74% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)74.01270
GSM780708Untreated after 4 days (C2_1)84.349173
GSM780709Untreated after 4 days (C3_1)82.847172
GSM780719Untreated after 4 days (C1_2)71.984670
GSM780720Untreated after 4 days (C2_2)94.015674
GSM780721Untreated after 4 days (C3_2)78.612271
GSM780710Trastuzumab treated after 4 days (T1_1)89.826574
GSM780711Trastuzumab treated after 4 days (T2_1)91.313474
GSM780712Trastuzumab treated after 4 days (T3_1)78.602271
GSM780722Trastuzumab treated after 4 days (T1_2)91.772974
GSM780723Trastuzumab treated after 4 days (T2_2)78.185471
GSM780724Trastuzumab treated after 4 days (T3_2)84.118973
GSM780713Pertuzumab treated after 4 days (P1_1)86.834773
GSM780714Pertuzumab treated after 4 days (P2_1)87.073773
GSM780715Pertuzumab treated after 4 days (P3_1)86.469173
GSM780725Pertuzumab treated after 4 days (P1_2)78.424971
GSM780726Pertuzumab treated after 4 days (P2_2)81.466372
GSM780727Pertuzumab treated after 4 days (P3_2)82.260472
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)81.039272
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)74.517270
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)94.503674
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)66.178268
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)93.946874